Needham Reiterates Buy on Harmony Biosciences, Maintains $53 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $53.
November 01, 2023 | 10:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Harmony Biosciences and maintained a price target of $53.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $53 price target indicates a positive outlook for Harmony Biosciences. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100